Syndax Pharmaceuticals SNDX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's interest expense?
- Syndax Pharmaceuticals (SNDX) reported interest expense of $0 in Q1 2026.
- How has Syndax Pharmaceuticals's interest expense changed year-over-year?
- Syndax Pharmaceuticals's interest expense decreased by 100.0% year-over-year, from $2K to $0.
- What is the long-term trend for Syndax Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's interest expense has grown at a -76.3% compound annual growth rate (CAGR), from $1.91M to $6K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.